modelAtovaquone

Extends from Pharmacolibrary.Drugs.ATC.P.P01AX06.

Information

name:Atovaquone
ATC code:P01AX06
route:oral
compartments:2
dosage:750mg
volume of distribution:8.8L
clearance:0.15L/h/kg
other parameters in model implementation

Atovaquone is a hydroxynaphthoquinone antiprotozoal medication primarily used for the treatment and prevention of Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis, and in combination with proguanil for malaria treatment and prophylaxis. It is approved for use in many countries.

Pharmacokinetics

Population pharmacokinetic model of atovaquone in healthy adult volunteers after oral administration.

References

  1. Hussein, Z, et al., & Canfield, CJ (1997). Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clinical pharmacology and therapeutics 61(5) 518–530. DOI:10.1016/S0009-9236(97)90132-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9164414

  2. Hussein, Z, et al., & Canfield, CJ (1996). Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. British journal of clinical pharmacology 42(5) 589–597. DOI:10.1111/j.1365-2125.1996.tb00114.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/8951190

  3. McGready, R, et al., & Nosten, F (2003). The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. European journal of clinical pharmacology 59(7) 545–552. DOI:10.1007/s00228-003-0652-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12955371

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)